Search
Huadong Medicine Subsidiary Secures FDA Approval for New Drug Clinical Trial in the US
2025-06-09 /
Read about 0 minute
Author：小编
The wholly-owned subsidiary of Huadong Medicine, Hangzhou Sino-American East China Pharmaceutical Co., Ltd., has received approval from the United States Food and Drug Administration (FDA) for the clinical trial application of HDM1010 tablets. This approval paves the way for a Phase I clinical trial in the United States, focusing on type 2 diabetes. HDM1010 tablets represent a fixed-dose combination of HDM1002 and SGLT2 inhibitors, independently developed by Sino-American East China. These tablets are designed to improve glucose tolerance, lower blood sugar levels, and facilitate weight reduction.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
